Here's what traders should do now.
Previous tests were buying opportunities in October and May and June.
There are still pockets of strength if you're willing to dig deep, though it's crucial to have crystal-clear stop levels to avert serious losses.
The charts of the producer of medical technology show promise but could be derailed by weakness in the broader markets.
The shares of the oncology company look as though they have found a bottom.
The technical history of the stock is limited but buyers appear more aggressive than sellers.
Here's how to play this small-cap biotech that's targeting a type of kidney-related cancer.
There are reasons to be optimistic about Hims & Hers Health and OptiNose Inc.
A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.
The maker of clear orthodontic devices is scheduled to report second-quarter results after Wednesday's close.